Program
denikitug
Its studies are mostly in Adenocarcinoma Of Esophagus · Colorectal Neoplasms, led by Gilead Sciences.
Furthest: phase 2, since Apr 7, 20263 company-led studies, 3 open or runningNext primary completion: Dec 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciences | 33 open or running | phase 2since Apr 7, 2026 | Aug 11, 2021 | Dec 2028phase 2 · NCT07527858 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 11, 2021First study: phase 1 study in Advanced Solid TumorFirst studyNCT05007782 · 304 enrolled · United States, Australia, Canada and more
- Apr 7, 20262 phase 2 studiesPhase 2 reachedNCT07527858, NCT07546812
Ahead
- Dec 2028Primary completion: phase 2 study in Advanced Microsatellite Stable Colorectal CancerNCT07527858
- Dec 2028Primary completion: phase 1 study in Advanced Solid TumorNCT05007782
- Jan 2030Primary completion: phase 2 study in Adenocarcinoma Of EsophagusNCT07546812
TargetBeta
CCR8 →read by rule
“A humanized immunoglobulin G1 (IgG1) afucosylated monoclonal antibody against C-C-chemokine receptor 8 (CCR8), ”NCIt, by rule
Other programs on CCR8
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cafelkibart | Sino Biopharmaceutical | phase 3 | 7 |
| CCR8 Inhibitor IPG7236rule | nanjing-immunophage-biotech-co-ltd | phase 2 | 3 |
| imzokitug | Bristol-Myers Squibb | phase 2 | 2 |
| Anti-CCR8 Antibody-drug Conjugate TAK-188rule | Takeda | phase 2 | 1 |
| Anti-CCR8 Monoclonal Antibody HC006rule | hc-biopharma-inc | phase 1 | 2 |
| azirkitug | AbbVie | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07546812Adenocarcinoma Of Esophagus · United States, Australia, France and more | 2 | Active, not recruiting | Jan 2030 | 120 |
| NCT07527858Advanced Microsatellite Stable Colorectal Cancer · United States, Australia, South Korea and more | 2 | Recruiting | Dec 2028 | 170 |
| NCT05007782Advanced Solid Tumor · United States, Australia, Canada and more | 1 | Active, not recruiting | Dec 2028 | 304 |
How it is read
Names in the registry
- “Denikitug”, 3 entries
Conditions, from the studies’ own filings
- Adenocarcinoma Of Esophagus, 1 study
- Colorectal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.